Tags

Type your tag names separated by a space and hit enter

A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.
Arch Med Res. 2020 10; 51(7):631-635.AM

Abstract

The novel coronavirus 2019-nCoV (SARS-CoV-2) infection that emerged in China in December 2019 has rapidly spread to become a global pandemic. This article summarizes the potential benefits of erythropoietin (EPO) in alleviating SARS-CoV-2 pathogenesis which is now called COVID-19. As with other coronavirus infection, the lethality of COVID-19 is associated with respiratory dysfunction due to overexpression of proinflammatory cytokines induced by the host immune responses. The resulting cytokine storm leads to the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Erythropoietin, well known for its role in the regulation of erythropoiesis, may have protective effects against ALI/ARDS induced by viral and other pathogens. EPO exerts antiapoptotic and cytoprotective properties under various pathological conditions. With a high safety profile, EPO promotes the production of endothelial progenitor cells and reduce inflammatory processes through inhibition of the nuclear factor-κB (NF-κB) and JAK-STAT3 signaling pathways. Thus, it may be considered as a safe drug candidate for COVID-19 patients if given at the early stage of the disease. The potential effects of erythropoietin on different aspects of ALI/ARDS associated with SARS-CoV-2 infection are reviewed.

Authors+Show Affiliations

Clinical Research Center, Department of Internal Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. Electronic address: masoomehsahebnasagh@gmail.com.Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.Department of Anesthesiology and Critical Care Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.Department of Orthopedic Surgery, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.Department of Surgery, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.Pharmacognosy Research Laboratories and Herbal Analysis Services UK, University of Greenwich, Kent, UK.Research Center for functional Genomics, Biomedicine and Translational Medicine, The Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; The Functional Genomics Department-The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania.Division of Translational Medicine, Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran; Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: Nabavi208@gmail.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32863034

Citation

Sahebnasagh, Adeleh, et al. "A Perspective On Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients With COVID-19." Archives of Medical Research, vol. 51, no. 7, 2020, pp. 631-635.
Sahebnasagh A, Mojtahedzadeh M, Najmeddin F, et al. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19. Arch Med Res. 2020;51(7):631-635.
Sahebnasagh, A., Mojtahedzadeh, M., Najmeddin, F., Najafi, A., Safdari, M., Rezai Ghaleno, H., Habtemariam, S., Berindan-Neagoe, I., & Nabavi, S. M. (2020). A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19. Archives of Medical Research, 51(7), 631-635. https://doi.org/10.1016/j.arcmed.2020.08.002
Sahebnasagh A, et al. A Perspective On Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients With COVID-19. Arch Med Res. 2020;51(7):631-635. PubMed PMID: 32863034.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19. AU - Sahebnasagh,Adeleh, AU - Mojtahedzadeh,Mojataba, AU - Najmeddin,Farhad, AU - Najafi,Atabak, AU - Safdari,Mohammadreza, AU - Rezai Ghaleno,Hassan, AU - Habtemariam,Solomon, AU - Berindan-Neagoe,Ioana, AU - Nabavi,Seyed Mohammad, Y1 - 2020/08/11/ PY - 2020/06/01/received PY - 2020/07/26/revised PY - 2020/08/05/accepted PY - 2020/8/31/pubmed PY - 2020/12/15/medline PY - 2020/9/1/entrez KW - Acute lung injury KW - Acute respiratory distress syndrome KW - COVID-19 KW - Erythropoietin KW - SARS-CoV-2 SP - 631 EP - 635 JF - Archives of medical research JO - Arch Med Res VL - 51 IS - 7 N2 - The novel coronavirus 2019-nCoV (SARS-CoV-2) infection that emerged in China in December 2019 has rapidly spread to become a global pandemic. This article summarizes the potential benefits of erythropoietin (EPO) in alleviating SARS-CoV-2 pathogenesis which is now called COVID-19. As with other coronavirus infection, the lethality of COVID-19 is associated with respiratory dysfunction due to overexpression of proinflammatory cytokines induced by the host immune responses. The resulting cytokine storm leads to the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Erythropoietin, well known for its role in the regulation of erythropoiesis, may have protective effects against ALI/ARDS induced by viral and other pathogens. EPO exerts antiapoptotic and cytoprotective properties under various pathological conditions. With a high safety profile, EPO promotes the production of endothelial progenitor cells and reduce inflammatory processes through inhibition of the nuclear factor-κB (NF-κB) and JAK-STAT3 signaling pathways. Thus, it may be considered as a safe drug candidate for COVID-19 patients if given at the early stage of the disease. The potential effects of erythropoietin on different aspects of ALI/ARDS associated with SARS-CoV-2 infection are reviewed. SN - 1873-5487 UR - https://www.unboundmedicine.com/medline/citation/32863034/A_Perspective_on_Erythropoietin_as_a_Potential_Adjuvant_Therapy_for_Acute_Lung_Injury/Acute_Respiratory_Distress_Syndrome_in_Patients_with_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0188-4409(20)30944-9 DB - PRIME DP - Unbound Medicine ER -